This site is intended for Healthcare Professionals only

Lords amendment tabled to open up self-injectable reclassification

Lords amendment tabled to open up self-injectable reclassification

Baroness Ritchie of Downpatrick has tabled a new clause to the Health Bill at committee stage in the House of Lords that would make self-injectable medicines eligible for reclassification from prescription-only to pharmacy status.

The new clause would amend the Human Medicines Regulations 2012 to enable self-injectable medicines to be considered for reclassification on a case-by-case basis.

Any reclassification would remain subject to assessment and approval by the Medicines and Healthcare products Regulatory Agency (MHRA).

This follows a call last month from Proprietary Association of Great Britain (PAGB) CEO Michelle Riddalls, at the Association of the European Self-Care Industry (AESGP) conference in Brussels, who urged modernisation of regulation that currently blocks the reclassification of injectable medicines.

“Healthcare has changed dramatically over the last few decades, but the legislation governing medicines classification has not kept pace,” she said.

“Self-administered injectable medicines are becoming increasingly common, yet under the current rules they cannot even be considered for reclassification in the UK, regardless of any evidence supporting their safe use. The underlying legislation was developed in a very different era, with the current UK prescription criteria dating back to 1968.

“The reality is that healthcare, technology and patient capability have changed significantly. The regulatory framework now needs to evolve to reflect that change and create the opportunity for companies to pursue these types of reclassifications.

“That is why PAGB is calling for changes to medicines legislation, including the criteria that determine prescription-only medicine status, so that self-administered injectable medicines can be considered for pharmacy reclassification, where supported by evidence. This is not about lowering standards or creating an automatic route to pharmacy availability. All applications would still need to undergo the same rigorous MHRA assessment and demonstrate that the benefits clearly outweigh the risks.

“By removing this legislative barrier, we have an opportunity to unlock one of the most significant advances in medicines reclassification for a generation, opening the door to a new wave of pharmacy medicine innovation and helping more people to self-care and access appropriate treatments through community pharmacy.”

The committee stage is provisionally due to finish on 25 November

Share:

Change privacy settings